|
gptkbp:instance_of
|
gptkb:diabetes
|
|
gptkbp:administered_by
|
subcutaneous injection
|
|
gptkbp:appearance
|
colorless solution
|
|
gptkbp:approves
|
gptkb:2000
gptkb:FDA
|
|
gptkbp:available_in
|
vials
pre-filled pens
|
|
gptkbp:brand
|
gptkb:insulin_glargine
|
|
gptkbp:class
|
long-acting insulin
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
basal insulin therapy
insulin regimen
|
|
gptkbp:color
|
clear
|
|
gptkbp:contraindication
|
hypersensitivity to insulin glargine
|
|
gptkbp:dosage_form
|
injection
|
|
gptkbp:duration
|
up to 24 hours
|
|
gptkbp:form
|
gptkb:Software_Solutions
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lantus
|
|
gptkbp:ingredients
|
gptkb:insulin_glargine
|
|
gptkbp:interacts_with
|
gptkb:beer
beta-blockers
other antidiabetic medications
|
|
gptkbp:invention
|
gptkb:2020
|
|
gptkbp:is_a_guide_for
|
EASD guidelines
ADA Standards of Medical Care
|
|
gptkbp:manufacturer
|
gptkb:Sanofi
|
|
gptkbp:marketed_as
|
many countries
|
|
gptkbp:mechanism_of_action
|
replaces insulin
|
|
gptkbp:p_hlevel
|
4.0 to 4.5
|
|
gptkbp:packaging
|
single-use pen
multi-dose vial
|
|
gptkbp:patient_population
|
gptkb:children
adults
|
|
gptkbp:pharmacokinetics
|
steady-state concentration
lowering blood glucose
|
|
gptkbp:premiered_on
|
1 to 2 hours
|
|
gptkbp:previous_name
|
gptkb:insulin_glargine
|
|
gptkbp:replaces
|
gptkb:Basaglar
gptkb:Toujeo
other long-acting insulins
|
|
gptkbp:requires
|
gptkb:true
|
|
gptkbp:service_frequency
|
once daily
|
|
gptkbp:shelf_life
|
28 days after opening
unopened 2 to 8 degrees Celsius
|
|
gptkbp:side_effect
|
gptkb:lipodystrophy
allergic reactions
weight gain
injection site reactions
hypoglycemia
edema
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:used_for
|
gptkb:diabetes
|
|
gptkbp:bfsParent
|
gptkb:diabetes
gptkb:Sanofi
|
|
gptkbp:bfsLayer
|
4
|